Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2015-07-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
第六届董事会第二次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Beijing Shuanglu Pharmaceutical Co., Ltd. It details the board's approval of an investment decision involving capital contribution to another company. The document includes meeting dates, attendance, and the resolution passed. There is no financial report, earnings data, or regulatory filing of financial results. It is not an annual or interim report, nor an earnings release. The content focuses on a board decision, specifically about investment approval, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is MANG with high confidence.
2015-07-07 Chinese
2014年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Implementation Announcement" for the year 2014 by Beijing SL Pharmaceutical Co., Ltd. It details the dividend distribution plan approved at the 2014 Annual General Meeting held on May 28, 2015, including specifics on stock dividends, cash dividends, record dates, and shareholding changes. The document is an announcement of the implementation of the dividend distribution scheme rather than the full annual report or financial statements. It is relatively short (2333 characters) and focuses on dividend details and shareholder information. Therefore, it fits the category of Notice of Dividend Amount (DIV) rather than an Annual Report (10-K) or Earnings Release (ER).
2015-07-07 Chinese
独立董事关于出资1800万元投资上海信忠医药科技有限公司参与其增资扩股的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from the independent directors of Beijing SL Pharmaceutical Co., Ltd. regarding the company's investment of 18 million yuan in Shanghai Xinzhong Pharmaceutical Technology Co., Ltd. It references compliance with regulatory guidelines and company bylaws, and it is an approval statement for a specific investment decision. The document is short (573 characters) and does not contain financial statements or detailed financial data. It is not a full report but rather a formal opinion or announcement related to a capital investment decision. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2015-07-07 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing SL Pharmaceutical Co., Ltd. regarding an external investment of 18 million RMB into Shanghai Xinzhong Pharmaceutical Technology Co., Ltd. It details the investment amount, purpose, risks, agreement terms, and impact on the company. The text includes specifics about the investment agreement, shareholder rights, and financial commitments but does not contain financial statements or quarterly/yearly financial results. It is a formal disclosure of a capital investment transaction rather than a financial report or earnings release. The document is not a full annual or interim report, audit report, or earnings release. It is not a regulatory certification or voting result announcement. The content fits best under Capital/Financing Update (CAP) as it provides detailed information about the company's financing activity and capital structure changes related to the investment.
2015-07-07 Chinese
股份变动报告书
Transaction in Own Shares Classification · 95% confidence The document is titled '股份变动报告书' which translates to 'Shareholding Change Report'. It details the company's share repurchase (buyback) activities, including the number of shares repurchased, changes in shareholding structure, and the cancellation of repurchased shares. It references relevant laws and regulations governing share repurchases and provides detailed tables of shareholding before and after the repurchase. The document does not contain financial statements or earnings data but focuses on the company's transaction in its own shares. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is 2878 characters, which is consistent with a detailed transaction report rather than a brief announcement or a full financial report.
2015-07-03 Chinese
关于第二大股东新乡白鹭化纤集团有限责任公司部分股权质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's second largest shareholder. It details specific share pledge transactions, dates, and amounts but does not contain financial statements or performance data. The content is about share pledge status and related financing guarantees, which fits the category of Capital/Financing Update rather than a full financial report or regulatory filing. The document length is short (1881 characters) and it is a direct announcement, not a report publication or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-06-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.